

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version 6.1      Revision Date: 30.09.2023      SDS Number: 595278-00019      Date of last issue: 06.03.2023  
Date of first issue: 04.04.2016

---

**SECTION 1. PRODUCT AND COMPANY IDENTIFICATION**

Product name : Ertugliflozin (< 2%) / Sitagliptin Formulation

**Manufacturer or supplier's details**

Company name of supplier : MSD  
Address : Avenida 16 de Septiembre No. 301  
Xaltocan - Xochimilco Mexico 16090  
Telephone : +52 55 57284444  
Emergency telephone : 1-908-423-6000  
E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical  
Restrictions on use : Not applicable

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification**

Skin corrosion/irritation : Category 2  
Serious eye damage/eye irritation : Category 2A  
Skin sensitization : Category 1  
Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Kidney, Stomach, Prostate)

**GHS label elements**

Hazard pictograms :  

Signal Word : Warning

Hazard Statements : H315 Causes skin irritation.  
H317 May cause an allergic skin reaction.  
H319 Causes serious eye irritation.  
H373 May cause damage to organs (Kidney, Stomach, Prostate) through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**  
P260 Do not breathe dust.  
P264 Wash skin thoroughly after handling.  
P272 Contaminated work clothing should not be allowed out of the workplace.  
P280 Wear protective gloves/ eye protection/ face protection.  
**Response:**  
P302 + P352 IF ON SKIN: Wash with plenty of water.

---

## Ertugliflozin (&lt; 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.03.2023
6.1	30.09.2023	595278-00019	Date of first issue: 04.04.2016

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P314 Get medical advice/ attention if you feel unwell.

P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.

P337 + P313 If eye irritation persists: Get medical advice/ attention.

P362 + P364 Take off contaminated clothing and wash it before reuse.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards**

May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Sitagliptin	654671-77-9	>= 30 -< 50
Cellulose	9004-34-6	>= 30 -< 50
Ertugliflozin	1210344-83-4	>= 1 -< 3
Magnesium stearate	557-04-0	>= 1 -< 5
Propyl 3,4,5-trihydroxybenzoate	121-79-9	>= 0.1 -< 1

**SECTION 4. FIRST AID MEASURES**

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms	:	Causes skin irritation.

## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.03.2023
6.1	30.09.2023	595278-00019	Date of first issue: 04.04.2016

and effects, both acute and delayed		May cause an allergic skin reaction. Causes serious eye irritation. May cause damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Metal oxides Oxides of phosphorus
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and

## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.03.2023
6.1	30.09.2023	595278-00019	Date of first issue: 04.04.2016

disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
Do not breathe dust.  
Do not swallow.  
Do not get in eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Contaminated work clothing should not be allowed out of the workplace.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labeled containers.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Sitagliptin	654671-77-9	TWA	0.5 mg/m <sup>3</sup> (OEB 2)	Internal

## Ertugliflozin (&lt; 2%) / Sitagliptin Formulation

Version 6.1      Revision Date: 30.09.2023      SDS Number: 595278-00019      Date of last issue: 06.03.2023  
 Date of first issue: 04.04.2016

Cellulose	9004-34-6	VLE-PPT	10 mg/m <sup>3</sup>	NOM-010-STPS-2014
		TWA	10 mg/m <sup>3</sup>	ACGIH
Ertugliflozin	1210344-83-4	TWA	10 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal
Magnesium stearate	557-04-0	VLE-PPT	10 mg/m <sup>3</sup>	NOM-010-STPS-2014
		TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
 Minimize open handling.

**Personal protective equipment**

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : powder

Color : No data available

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.03.2023
6.1	30.09.2023	595278-00019	Date of first issue: 04.04.2016

---

Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version 6.1      Revision Date: 30.09.2023      SDS Number: 595278-00019      Date of last issue: 06.03.2023  
Date of first issue: 04.04.2016

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.  
Chemical stability : Stable under normal conditions.  
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.  
Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.  
Incompatible materials : Oxidizing agents  
Hazardous decomposition products : No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION****Information on likely routes of exposure**

Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg  
Method: Calculation method

**Components:****Sitagliptin:**

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg  
LD50 (Mouse): 3,000 mg/kg

**Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

**Ertugliflozin:**

Acute oral toxicity : LD50 (Rat): 500 mg/kg  
Acute inhalation toxicity : Remarks: No data available

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.03.2023
6.1	30.09.2023	595278-00019	Date of first issue: 04.04.2016

---

Acute dermal toxicity : Remarks: No data available

**Magnesium stearate:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Remarks: Based on data from similar materials

**Propyl 3,4,5-trihydroxybenzoate:**

Acute oral toxicity : LD50 (Mouse, female): > 1,000 - 2,000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity

**Skin corrosion/irritation**

Causes skin irritation.

**Components:****Sitagliptin:**

Species : Rabbit  
Method : Draize Test  
Result : No skin irritation

**Ertugliflozin:**

Result : Corrosive

**Magnesium stearate:**

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

**Propyl 3,4,5-trihydroxybenzoate:**

Species : reconstructed human epidermis (RhE)  
Method : OECD Test Guideline 439

Result : No skin irritation

**Serious eye damage/eye irritation**

Causes serious eye irritation.



**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version 6.1      Revision Date: 30.09.2023      SDS Number: 595278-00019      Date of last issue: 06.03.2023  
Date of first issue: 04.04.2016

---

**Components:****Sitagliptin:**

Species : Rabbit  
Result : Irritating to eyes.  
Method : Draize Test

**Ertugliflozin:**

Result : Severe irritation

**Magnesium stearate:**

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials

**Propyl 3,4,5-trihydroxybenzoate:**

Species : Rabbit  
Result : Irreversible effects on the eye  
Method : OECD Test Guideline 405

**Respiratory or skin sensitization****Skin sensitization**

May cause an allergic skin reaction.

**Respiratory sensitization**

Not classified based on available information.

**Components:****Sitagliptin:**

Test Type : Local lymph node assay (LLNA)  
Species : Mouse  
Method : OECD Test Guideline 429  
Result : Not a skin sensitizer.

**Ertugliflozin:**

Test Type : Local lymph node assay (LLNA)  
Result : Not a skin sensitizer.

**Magnesium stearate:**

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Method : OECD Test Guideline 406  
Result : negative  
Remarks : Based on data from similar materials

**Propyl 3,4,5-trihydroxybenzoate:**

Test Type : Local lymph node assay (LLNA)

## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.03.2023
6.1	30.09.2023	595278-00019	Date of first issue: 04.04.2016

---

Routes of exposure : Skin contact  
 Species : Mouse  
 Result : positive

Assessment : Probability or evidence of skin sensitization in humans

### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### Sitagliptin:

Genotoxicity in vitro : Test Type: Ames test  
 Result: negative

Test Type: Chromosome aberration test in vitro  
 Test system: Chinese hamster ovary cells  
 Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
 Test system: rat hepatocytes  
 Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
 Species: Mouse  
 Application Route: Oral  
 Result: negative

#### Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative

Test Type: In vitro mammalian cell gene mutation test  
 Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
 Species: Mouse  
 Application Route: Ingestion  
 Result: negative

#### Ertugliflozin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative

Test Type: Chromosome aberration test in vitro  
 Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
 Species: Rat  
 Result: negative

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.03.2023
6.1	30.09.2023	595278-00019	Date of first issue: 04.04.2016

---

**Magnesium stearate:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

**Propyl 3,4,5-trihydroxybenzoate:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: positive

Test Type: Chromosome aberration test in vitro  
Result: positive

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Result: negative

Test Type: In vitro sister chromatid exchange assay in mammalian cells  
Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****Sitagliptin:**

Species : Mouse  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

Species : Rat  
Application Route : oral (drinking water)  
Exposure time : 2 Years

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version 6.1      Revision Date: 30.09.2023      SDS Number: 595278-00019      Date of last issue: 06.03.2023  
Date of first issue: 04.04.2016

---

Result : positive  
Target Organs : Liver  
Remarks : Significant toxicity observed in testing

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

**Cellulose:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

**Ertugliflozin:**

Species : Mouse  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

**Propyl 3,4,5-trihydroxybenzoate:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 103 weeks  
Result : negative

**Reproductive toxicity**

Not classified based on available information.

**Components:****Sitagliptin:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL Parent: 1,000 mg/kg body weight  
Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Teratogenicity: LOAEL: 250 mg/kg body weight  
Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects.

## Ertugliflozin (&lt; 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.03.2023
6.1	30.09.2023	595278-00019	Date of first issue: 04.04.2016

---

Test Type: Embryo-fetal development  
 Species: Rabbit  
 Teratogenicity: NOAEL: 125 mg/kg body weight  
 Result: No teratogenic effects.

**Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

**Ertugliflozin:**

Effects on fertility : Test Type: Fertility/early embryonic development  
 Species: Rat  
 Application Route: Oral  
 Fertility: NOAEL: 250 mg/kg body weight  
 Remarks: Maternal toxicity observed.  
 No significant adverse effects were reported

Test Type: Fertility/early embryonic development  
 Species: Rabbit  
 Application Route: Oral  
 Fertility: NOAEL: 200 mg/kg body weight  
 Remarks: No significant adverse effects were reported

Effects on fetal development : Test Type: Embryo-fetal development  
 Species: Rat  
 Application Route: Oral  
 Developmental Toxicity: NOAEL: 50 mg/kg body weight  
 Remarks: Adverse developmental effects were observed

Test Type: Embryo-fetal development  
 Species: Rabbit  
 Application Route: Oral  
 Developmental Toxicity: NOAEL: 250 mg/kg body weight  
 Remarks: No significant adverse effects were reported

**Magnesium stearate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
 Species: Rat  
 Application Route: Ingestion  
 Method: OECD Test Guideline 422  
 Result: negative  
 Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development  
 Species: Rat

## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.03.2023
6.1	30.09.2023	595278-00019	Date of first issue: 04.04.2016

---

Application Route: Ingestion  
 Result: negative  
 Remarks: Based on data from similar materials

### Propyl 3,4,5-trihydroxybenzoate:

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

Effects on fetal development : Test Type: Embryo-fetal development  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

### STOT-single exposure

Not classified based on available information.

### STOT-repeated exposure

May cause damage to organs (Kidney, Stomach, Prostate) through prolonged or repeated exposure if swallowed.

### Components:

#### Ertugliflozin:

Routes of exposure : Oral  
 Target Organs : Kidney, Stomach, Prostate  
 Assessment : May cause damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

### Components:

#### Sitagliptin:

Species : Mouse  
 NOAEL : 500 mg/kg  
 LOAEL : 1,000 mg/kg  
 Application Route : Oral  
 Exposure time : > 2 y  
 Target Organs : Kidney

Species : Rat  
 NOAEL : 500 mg/kg  
 LOAEL : 1,000 mg/kg  
 Application Route : Oral  
 Exposure time : 14 Weeks  
 Target Organs : Liver, Kidney, Heart, Teeth

Species : Dog  
 NOAEL : 10 mg/kg  
 LOAEL : 50 mg/kg  
 Application Route : Oral  
 Exposure time : 53 Weeks

## Ertugliflozin (&lt; 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.03.2023
6.1	30.09.2023	595278-00019	Date of first issue: 04.04.2016

---

Target Organs : Central nervous system  
 Symptoms : Loss of balance  
 Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Dog  
 NOAEL : 2 mg/kg  
 LOAEL : 10 mg/kg  
 Application Route : Oral  
 Exposure time : 27 Weeks  
 Target Organs : Skeletal muscle, Central nervous system  
 Symptoms : Loss of balance  
 Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Monkey  
 NOAEL : 100 mg/kg  
 Application Route : Oral  
 Exposure time : 14 Weeks  
 Remarks : No significant adverse effects were reported

**Cellulose:**

Species : Rat  
 NOAEL : >= 9,000 mg/kg  
 Application Route : Ingestion  
 Exposure time : 90 Days

**Ertugliflozin:**

Species : Rat  
 LOAEL : 500 mg/kg  
 Application Route : Oral  
 Exposure time : 30 d

Species : Rat  
 LOAEL : 250 mg/kg  
 Application Route : Oral  
 Exposure time : 30 d  
 Target Organs : Kidney

Species : Rat  
 LOAEL : 25 mg/kg  
 Application Route : Oral  
 Exposure time : 180 d  
 Target Organs : Kidney, Bone, Stomach

Species : Rat  
 LOAEL : 25 mg/kg  
 Exposure time : 90 d  
 Target Organs : Kidney, Gastrointestinal tract, Prostate

Species : Dog  
 NOAEL : 150 mg/kg  
 Application Route : Oral

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version 6.1      Revision Date: 30.09.2023      SDS Number: 595278-00019      Date of last issue: 06.03.2023  
Date of first issue: 04.04.2016

---

Exposure time : 270 d  
Remarks : No significant adverse effects were reported

Species : Mouse  
NOAEL : 100 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

Species : Mouse  
NOAEL : 100 mg/kg  
Application Route : Oral  
Exposure time : 28 d  
Target Organs : Bone  
Remarks : No significant adverse effects were reported

**Magnesium stearate:**

Species : Rat  
NOAEL : > 100 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Remarks : Based on data from similar materials

**Propyl 3,4,5-trihydroxybenzoate:**

Species : Rat  
NOAEL : 135 mg/kg  
Application Route : Ingestion  
Exposure time : 13 Weeks

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Sitagliptin:**

Inhalation : Symptoms: upper respiratory tract infection, pharyngitis, Headache  
Ingestion : Symptoms: upper respiratory tract infection, nasopharyngitis, Headache, Nausea, Abdominal pain, Diarrhea

**Ertugliflozin:**

Ingestion : Symptoms: The most common side effects are:, Headache, constipation, Diarrhea, Nausea, urinary tract infection, muscle pain, upper respiratory tract infection

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Sitagliptin:**



**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version 6.1      Revision Date: 30.09.2023      SDS Number: 595278-00019      Date of last issue: 06.03.2023  
Date of first issue: 04.04.2016

---

- Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 60 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 39 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201
- NOEC (Pseudokirchneriella subcapitata (green algae)): 2.2 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201
- Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l  
Exposure time: 33 d  
Method: OECD Test Guideline 210
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 9.8 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211
- Toxicity to microorganisms : EC50: > 150 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209
- NOEC: 150 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition

**Cellulose:**

- Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

**Ertugliflozin:**

- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 77 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201
- NOEC (Pseudokirchneriella subcapitata (green algae)): 50 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201
- Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 1 mg/l  
Exposure time: 32 d  
Method: OECD Test Guideline 210

## Ertugliflozin (&lt; 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.03.2023
6.1	30.09.2023	595278-00019	Date of first issue: 04.04.2016

---

Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 2.14 mg/l  
 Exposure time: 21 d  
 Method: OECD Test Guideline 211  
 Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 1,000 mg/l  
 Exposure time: 3 h  
 Test Type: Respiration inhibition  
 Method: OECD Test Guideline 209

NOEC: 1,000 mg/l  
 Exposure time: 3 h  
 Test Type: Respiration inhibition  
 Method: OECD Test Guideline 209

**Magnesium stearate:**

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
 Exposure time: 48 h  
 Method: DIN 38412  
 Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
 Exposure time: 47 h  
 Test substance: Water Accommodated Fraction  
 Method: Directive 67/548/EEC, Annex V, C.2.  
 Remarks: Based on data from similar materials  
 No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
 Exposure time: 72 h  
 Test substance: Water Accommodated Fraction  
 Method: OECD Test Guideline 201  
 Remarks: Based on data from similar materials  
 No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
 Exposure time: 72 h  
 Test substance: Water Accommodated Fraction  
 Method: OECD Test Guideline 201  
 Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l  
 Exposure time: 16 h  
 Test substance: Water Accommodated Fraction  
 Remarks: Based on data from similar materials

**Propyl 3,4,5-trihydroxybenzoate:**

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 19.06 mg/l  
 Exposure time: 48 h

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version 6.1      Revision Date: 30.09.2023      SDS Number: 595278-00019      Date of last issue: 06.03.2023  
Date of first issue: 04.04.2016

---

- Test substance: Neutralized product  
Method: OECD Test Guideline 202
- Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): 0.37 mg/l  
Exposure time: 72 h  
Test substance: Neutralized product  
Method: OECD Test Guideline 201
- EC10 (Pseudokirchneriella subcapitata (green algae)): 0.17 mg/l  
Exposure time: 72 h  
Test substance: Neutralized product  
Method: OECD Test Guideline 201
- Toxicity to microorganisms : EC50: 636 mg/l  
Exposure time: 3 h  
Method: OECD Test Guideline 209

**Persistence and degradability****Components:****Sitagliptin:**

- Biodegradability : Result: not rapidly degradable  
Biodegradation: 39.7 %  
Exposure time: 28 d  
Method: OECD Test Guideline 314

- Stability in water : Hydrolysis: 50 %(401 d)  
Method: OECD Test Guideline 111

**Cellulose:**

- Biodegradability : Result: Readily biodegradable.

**Ertugliflozin:**

- Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 40.8 %  
Exposure time: 28 d

**Magnesium stearate:**

- Biodegradability : Result: Not biodegradable  
Remarks: Based on data from similar materials

**Propyl 3,4,5-trihydroxybenzoate:**

- Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 49.4 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301F

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.03.2023
6.1	30.09.2023	595278-00019	Date of first issue: 04.04.2016

---

**Bioaccumulative potential****Components:****Sitagliptin:**

Partition coefficient: n-octanol/water : log Pow: -0.03

**Ertugliflozin:**

Partition coefficient: n-octanol/water : log Pow: 2.47

**Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

**Propyl 3,4,5-trihydroxybenzoate:**

Partition coefficient: n-octanol/water : log Pow: 1.8  
Remarks: Calculation

**Mobility in soil****Components:****Sitagliptin:**

Distribution among environmental compartments : log Koc: 4.37

**Ertugliflozin:**

Distribution among environmental compartments : log Koc: 2.88

**Other adverse effects**

No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

---

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.03.2023
6.1	30.09.2023	595278-00019	Date of first issue: 04.04.2016

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Domestic regulation****NOM-002-SCT**

Not regulated as a dangerous good

**Special precautions for user**

Not applicable

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

Federal Law for the control of chemical precursors, essential chemical products and machinery for producing capsules, tablets and pills. : Not applicable

**The ingredients of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

**SECTION 16. OTHER INFORMATION**

Revision Date : 30.09.2023

Date format : dd.mm.yyyy

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

NOM-010-STPS-2014 : Mexico. Norm NOM-010-STPS-2014 on Chemicals Polluting the Work Environment - Identification, Assessment and Control - Appendix 1 Occupational Exposure Limits

ACGIH / TWA : 8-hour, time-weighted average

NOM-010-STPS-2014 / VLE- : Time weighted average limit value

PPT

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Or-

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.03.2023
6.1	30.09.2023	595278-00019	Date of first issue: 04.04.2016

---

ganisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8